Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Ther Res Clin Exp ; 98: 100690, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36712177

RESUMEN

Background: A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information re- garding their appropriate use and prescription that should be considered in clinical practice for impetigo management. Objective: A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information regarding their appropriate use and prescription that should be considered in clinical practice for impetigo management. Methods: A consensus on ideal features of antibiotic therapy for the treatment of impetigo was appraised by an online Delphi-based method, based on a panel of 61 infectious disease specialists, pediatricians, and dermatologists coordinated by a scientific committee of 5 experts specializing in impetigo management. Results: Full or very high consensus was reached on the 10 statements identified to describe the characteristics of the best hypothetic antibiotic therapy for impetigo together with indications for appropriate antibiotics use. Conclusions: Several criteria have to be considered when selecting topical antibacterial therapy for impetigo. Beyond efficacy and safety, antimicrobial susceptibility and pharmacological characteristics of the agent are essential points. Formulation of the antimicrobial product is fundamental, as well as patient and caregiver preference, to facilitate therapeutic adherence, to achieve the infection control, and to obtain the best benefit from treatment (Curr Ther Res Clin Exp. 2023; 84:XXXXXX).

2.
Minerva Pediatr ; 68(6): 412-418, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27768013

RESUMEN

BACKGROUND: Contact dermatitis can be defined as an inflammatory process affecting the skin surface and induced by contact with chemical, physical and/or biotic agents in the environment. It causes lesions to skin, mucosae and semi-mucosae by means of allergic and irritant pathogenic mechanisms. Among the main triggers of contact dermatitis in the pediatric age are chemical or physical agents, which cause irritant contact dermatitis (ICD), and sensitizers, which cause a tissue damage through an allergic mechanism (allergic contact dermatitis [ACD]). METHODS: A prospective, multicenter, observational study was carried out in 204 children affected by contact dermatitis, aged up to 14 years, and enrolled by pediatricians from 7 different Italian provinces. The diagnosis of contact dermatitis was based on the pediatrician's clinical evaluation. The data were collected through a series of simple and multiple choice questions, anonymously filled out by pediatricians. RESULTS: In 90% of cases (184 of 204 patients), there was complete remission of contact dermatitis, with no cases of worsening. No adverse events were observed, either. The effectiveness of the therapy was rated as "very effective" by 84.4% of the parents and 86.8% of the pediatricians. In only 10 patients a new therapy had to be prescribed. CONCLUSIONS: Contact dermatitis is a heterogeneous inflammatory skin disease induced by contact with different kinds of environmental agents. Cutaneous manifestations are highly variable and depend on the modality of contact, on the causative agent and on the pathogenesis. This Italian experience of a clinical approach to contact dermatitis stresses the need of daily skin care through different therapeutic strategies, based on the diagnosis, the clinical severity and the parents and children compliance. The first therapeutic measure to be implemented is prevention, through the removal of the causative agent and the use of protective devices. Indeed, preserving the skin's barrier function is an important goal and a priority of treatment algorithms.


Asunto(s)
Dermatitis Alérgica por Contacto/terapia , Dermatitis Irritante/terapia , Cooperación del Paciente , Adolescente , Adulto , Niño , Preescolar , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/etiología , Dermatitis Irritante/diagnóstico , Dermatitis Irritante/etiología , Femenino , Humanos , Lactante , Recién Nacido , Italia , Masculino , Estudios Prospectivos , Inducción de Remisión , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
6.
Sci Total Environ ; 946: 174491, 2024 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-38969118

RESUMEN

The escalating use of plastics in agriculture, driven by global population growth and increasing food demand, has concurrently led to a rise in Agricultural Plastic Waste (APW) production. Effective waste management is imperative, prompting this study to address the initial step of management, that is the quantification and localization of waste generated from different production systems in diverse regions. Focused on four Southern European countries (Italy, Spain, Greece, and Portugal) at the regional level, the study uses Geographic Information System (GIS), land use maps, indices tailored to each specific agricultural application and each crop type for plastic waste mapping. Furthermore, after the data was employed, it was validated by relevant stakeholders of the mentioned countries. The study revealed Spain, particularly the Andalusia region, as the highest contributor to APW equal to 324,000 tons per year, while Portugal's Azores region had the lowest estimate equal to 428 tons per year. Significantly, this research stands out as one of the first to comprehensively consider various plastic applications and detailed crop cultivations within the production systems, representing a pioneering effort in addressing plastic waste management in Southern Europe. This can lead further on to the management of waste in this area and the transfer of the scientific proposition to other countries.

7.
Anal Biochem ; 425(1): 13-7, 2012 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-22394617

RESUMEN

Celiac disease (CD) is an immune-mediated disorder affecting genetically predisposed subjects. It is caused by the ingestion of wheat gluten and related prolamins. A final diagnosis for this disease can be obtained by examination of jejunal biopsies. Nevertheless, different analytical approaches have been established to detect the presence of anti-tissue transglutaminase antibodies that represent a serological hallmark of the disease. In this work, we explored a new method for the diagnosis of CD based on the detection of serum anti-transglutaminase antibodies by resonance energy transfer (RET) between donor molecules and acceptor molecules. In particular, we labeled the liver transglutaminase (tTG) enzyme from guinea pig and the rabbit anti-tTG antibodies with a couple of fluorescence probes that are able to make RET if they are located within with Förster distance. We labeled tTG with the fluorescence probe DyLight 594 as donor and the anti-tTG antibodies with the fluorescence probe DyLight 649 as acceptor. However, due to the large size of the formed complex (tTG/anti-tTG), and consequently to the low efficiency energy transfer process between the donor-acceptor molecules, we explored a new experimental approach that allows us to extend the utilizable range of RET between donor:acceptor pairs by using one single molecule as donor and multiple molecules as energy acceptors, instead of using a single acceptor molecule as usually occurs in RET experiments. The obtained results clearly show that the use of one donor and multiacceptor strategy enables for a simple and rapid detection of serum anti-transglutaminase antibodies. In addition, our results point out that it is possible to consider this approach as a new method for a wide variety of analytical assays.


Asunto(s)
Enfermedad Celíaca/diagnóstico , Ensayo de Inmunoadsorción Enzimática/métodos , Transferencia Resonante de Energía de Fluorescencia , Animales , Autoanticuerpos/sangre , Enfermedad Celíaca/inmunología , Cobayas , Transglutaminasas/metabolismo
8.
J Chemother ; 34(5): 279-285, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34405763

RESUMEN

Bacterial impetigo is one of the most common skin infection in childhood. Uncertainty exists about its management. This article offers practical suggestions, given the existing evidence and experts' opinions, for correctly managing pediatric impetigo in both hospital and ambulatory settings. Italian physicians with an expertise on pediatric impetigo appointed a working group. A preliminary literature search using Pubmed/MEDLINE and Cochrane Library databases has been performed. The most common controversial issues about pediatric impetigo have been identified and then discussed from multidisciplinary perspectives, according to the 'structured controversy' methodology, a technique discovered and designed to get engaged in a controversy and then guide participants to seek consensus. The expert panels identified 10 main controversies about pediatric impetigo. All of them have been discussed from dermatological, pediatric, pharmacological and microbiological points of view reaching consensus. Each controversy has been revised thus giving practical issues for an easy use in clinical practice. Based on clinical experts' opinion, local epidemiology and literature review this article offers practical suggestions for the management of pediatric impetigo trying to reduce uncertainty in this setting of care.


Asunto(s)
Impétigo , Quinolonas , Aminopiridinas/farmacología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Celulitis (Flemón)/tratamiento farmacológico , Niño , Humanos , Impétigo/diagnóstico , Impétigo/tratamiento farmacológico , Quinolonas/farmacología
9.
Oncology ; 78 Suppl 1: 68-77, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20616587

RESUMEN

Most hepatocellular carcinomas (HCC) are diagnosed in patients with cirrhosis and/or when tumor burden is too advanced for surgical treatment. In many of these cases the only suitable therapy is locoregional, percutaneous and/or intraarterial treatment. Moreover, the best way to guide and assess response to locoregional HCC treatment are two issues under discussion today. First-generation and subsequent second-generation microbubble contrast agents, together with contrast-enhanced ultrasound (US) imaging, have expanded the role of US techniques in HCC treatments. In this review our purpose is to illustrate the advantages, limits and potential of contrast-enhanced US application for locoregional HCC treatment.


Asunto(s)
Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/terapia , Medios de Contraste , Compuestos Férricos , Hierro , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/terapia , Óxidos , Humanos , Resultado del Tratamiento , Ultrasonografía
10.
Clin Infect Dis ; 49(4): 498-506, 2009 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-19591593

RESUMEN

BACKGROUND: Analysis of hepatitis C virus (HCV) RNA kinetics during antiviral therapy may allow estimation of the probability of response. METHODS: To assess clinical and virological correlates and the predictive value of first-phase HCV RNA kinetics during pegylated interferon and ribavirin treatment, we studied 119 patients with chronic hepatitis C who were treated with pegylated interferon and ribavirin. HCV RNA level was measured 5 min before and 2, 14, and 28 days after the start of treatment. For each patient the Delta(t0-t2) log(10) HCV RNA value was calculated, which indicates the relative reduction in HCV RNA level from before treatment to day 2 after logarithmic transformation. RESULTS: A Delta(t0-t2) log(10) HCV RNA value < or =0.8 showed a 95% negative predictive value for virological response, whereas one >2.5 had a 93% positive predictive value for virological response, independent of genotype and histology. The Delta(t0-t2) log(10) HCV RNA value was strictly related to final treatment outcome and could differentiate not only patients with a sustained virological response from nonresponders but also patients who experienced relapse from the former. The Delta(t0-t2) log(10) HCV RNA value was highest among patients infected with genotypes 2 and 3 and was lowest among patients infected with genotype 1. It decreased with increasing grades of fibrosis and steatosis and was also inversely related to gamma-glutamyl transpeptidase (GGT) level and HOMA-IR (homeostasis model assessment for insulin resistance) score. In multivariate analysis, Delta(t0-t2) log(10) HCV RNA value was the strongest predictor of sustained virological response and appeared to be independently related to viral genotype and GGT level. CONCLUSION: HCV RNA kinetics has strong predictive value. It correlates with virological and clinical parameters that are known predictors of antiviral treatment outcome, including insulin resistance. The measurement of HCV load as early as 2 days after the start of pegylated interferon and ribavirin is a useful tool for the prediction of treatment outcome in individual patients and should be used in clinical practice.


Asunto(s)
Antivirales/uso terapéutico , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/tratamiento farmacológico , ARN Viral/sangre , Carga Viral , Adulto , Femenino , Hepatitis C Crónica/diagnóstico , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Polietilenglicoles/uso terapéutico , Valor Predictivo de las Pruebas , Pronóstico , Proteínas Recombinantes , Ribavirina/uso terapéutico , Resultado del Tratamiento
11.
J Med Virol ; 81(12): 2012-20, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19856471

RESUMEN

Co-infection with HBV and HCV seems to be associated with more severe liver disease in retrospective and cross-sectional studies in adults, but no data are available when co-infection is acquired in youth. The long-term outcome of infection acquired in youth was assessed in patients co-infected with HBV and HCV and in patients with HBV infection only. Twenty-seven patients with HBV and HCV co-infection and 27 patients infected with HBV only were enrolled. Seventy-six per cent of the patients were treated with alpha-interferon for 1 year. After a median follow-up of 23 years, the annual progression rate of fibrosis was 0.07 in patients co-infected with HBV and HCV, and in those infected with HBV it was 0.07 and 0.11 (P < 0.004) for HBe and anti-HBe-positive patients, respectively. In co-infected patients, the development of cirrhosis was observed in 2 (7.4%) and of hepatocellular carcinoma (HCC) in 1 (3.7%), while in those with HBV, cirrhosis appeared in one patient (3.7%). Alcohol intake (OR = 9.5 +/- 1.2; 95% CI = 6.6-13.9; P < 0.0001) was independently associated with cirrhosis and HCC. alpha-interferon showed no efficacy during treatment, but the treated group showed higher HCV RNA clearance during post-treatment follow-up. Co-infection with HBV and HCV and single HBV infection acquired in youth showed a low rate of progression to liver fibrosis, no liver failure, and low development of HCC during a median follow-up of 23 years (range 17-40).


Asunto(s)
Progresión de la Enfermedad , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/patología , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/patología , Adolescente , Adulto , Factores de Edad , Antivirales/administración & dosificación , Niño , Preescolar , Femenino , Fibrosis , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/epidemiología , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/epidemiología , Humanos , Interferón-alfa/administración & dosificación , Cirrosis Hepática/etiología , Masculino , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento
12.
Org Biomol Chem ; 7(3): 460-8, 2009 Feb 07.
Artículo en Inglés | MEDLINE | ID: mdl-19156310

RESUMEN

Molecular dynamics simulations have been performed for non-covalent complexes of phenyl beta-xylobioside with the retaining endo-beta-1,4-xylanase from B. circulans (BCX) and its Tyr69Phe mutant using a hybrid QM/MM methodology. A trajectory initiated for the wild-type enzyme-substrate complex with the proximal xylose ring bound at the -1 subsite (adjacent to the scissile glycosidic bond) in the (4)C(1) chair conformation shows spontaneous transformation to the (2,5)B boat conformation, and potential of mean force calculations indicate that the boat is approximately 30 kJ mol(-1) lower in free energy than the chair. Analogous simulations for the mutant lacking one oxygen atom confirm the key role of Tyr69 in stabilizing the boat in preference to the (4)C(1) chair conformation, with a relative free energy difference of about 20 kJ mol(-1), by donating a hydrogen bond to the endocyclic oxygen of the proximal xylose ring. QM/MM MD simulations for phenyl beta-xyloside in water, with and without a propionate/propionic acid pair to mimic the catalytic glutamate/glutamic acid pair of the enzyme, show the (4)C(1) chair to be stable, although a hydrogen bond between the OH group at C2 of xylose and the propionate moiety seems to provide some stabilization for the (2,5)B conformation.


Asunto(s)
Bacillus/enzimología , Dominio Catalítico , Endo-1,4-beta Xilanasas/química , Modelos Moleculares , Mutagénesis , Proteínas Mutantes/química , Tirosina/metabolismo , Biocatálisis , Biología Computacional , Simulación por Computador , Endo-1,4-beta Xilanasas/genética , Endo-1,4-beta Xilanasas/metabolismo , Estabilidad de Enzimas , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Teoría Cuántica , Tirosina/genética
13.
Can J Gastroenterol ; 23(4): 273-8, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19373421

RESUMEN

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C feature steatosis and insulin resistance (IR), conditions associated with the metabolic syndrome (MS). OBJECTIVES: To assess the prevalence of MS and determinants of IR in patients with NAFLD and chronic hepatitis C. METHODS: Ninety-three consecutive patients with NAFLD, 97 with chronic hepatitis C virus (HCV) genotypes 1 and 2, and 182 'healthy' controls without steatosis were enrolled in the present study. The prevalence of MS was assessed by modified Adult Treatment Panel III criteria and IR by the homeostasis model assessment of insulin resistance (HOMA-IR). IR was defined as the 75th percentile of the HOMA-IR of control subjects. RESULTS: While the prevalence of IR was similar in NAFLD and HCV-infected subjects (70.0% and 78.7%, respectively), the prevalence of MS was significantly higher in NAFLD patients than in HCV-infected patients (27.9% versus 4.1%) and in controls (5.6%). With multivariate analysis, IR was predicted by body mass index (OR 1.263; 95% CI 1.078 to 1.480) and triglyceridemia (OR 1.011; 95% CI 1.002 to 1.020) in NAFLD and by sex (OR for female sex 0.297; 95% CI 0.094 to 0.940) and fibrosis stage (OR 2.751; 95% CI 1.417 to 5.340) in chronic hepatitis C. CONCLUSIONS: IR is independently associated with body mass index and triglyceridemia in NAFLD, sex and fibrosis in chronic HCV infection, and has a higher prevalence in NAFLD and chronic hepatitis C than in controls. However, the frequency of MS in HCVinfected patients, similar to that of controls, is significantly lower than that seen in NAFLD patients. The current diagnostic criteria of MS are more likely to 'capture' patients with NAFLD than with chronic hepatitis C, although both groups are insulin resistant.


Asunto(s)
Hígado Graso/epidemiología , Hepatitis C Crónica/epidemiología , Resistencia a la Insulina , Síndrome Metabólico/epidemiología , Adulto , Índice de Masa Corporal , Estudios de Casos y Controles , Comorbilidad , Hígado Graso/sangre , Femenino , Genotipo , Hepacivirus/genética , Hepatitis C Crónica/sangre , Hepatitis C Crónica/virología , Humanos , Italia/epidemiología , Masculino , Síndrome Metabólico/sangre , Persona de Mediana Edad , Prevalencia , Factores Sexuales , Triglicéridos/sangre
14.
Recenti Prog Med ; 99(1): 19-26, 2008 Jan.
Artículo en Italiano | MEDLINE | ID: mdl-18389867

RESUMEN

More than 25% of cancer patients in western countries have less than 18 years old children. While increasing attention has been given to various psychosocial issues related to neoplastic disease, the impact of parental cancer on psychosocial 'functioning' of children and adolescents are still poorly explored. Similarly, the role of parenting concerns on quality of life, compliance to the disease and treatments and therapeutic choices are not sufficiently addressed. Usually, cancer patients are reluctant to openly inform their children about their disease. Such "protective" attitude may cause anxiety and psichological distress in children and affect the coping capability of the whole family. Lack of communication may increase the sense of sadness, grief and despair, experienced by children whose parents are ill and induce long-term psychological consequences. Parenthood, on the other side, carries additional concerns to cancer patients which may render disease management more challenging and painful. The oncology team must favour, through appropriate support programs, communication between patients and their children to ensure a better psychological outcome from a stressful situation deeply affecting quality of life of patients and their families.


Asunto(s)
Salud de la Familia , Relaciones Familiares , Neoplasias , Responsabilidad Parental , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Neoplasias/psicología , Neoplasias/terapia , Revelación de la Verdad
15.
Int J Dermatol ; 57(11): 1320-1323, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29974945

RESUMEN

BACKGROUND: Acne vulgaris is a chronic inflammatory skin disease of the pilosebaceous follicles that affects patients of all ages with a younger onset being more common than in the past. OBJECTIVES: To investigate on the prevalence, clinical features and treatments of acne in 9 to 14-year-old patients. METHODS: A prospective observational study was conducted between April 2016 and May 2016. The study population consisted of patients attending 32 different pediatric ambulatory clinics located in Italy (North: 56.25%, Center: 18.75%, South: 25%). For each patient, a specific questionnaire was registered: i) demographic data; ii) past personal history of acne; iii) auxologic parameters. Further data were gathered for patients suffering from acne at study enrollment: i) body areas involved by the disease; ii) acne severity evaluated through a 0-5 scale (Global Evaluation Acne scale); iii) acne treatments. RESULTS: A total of 683 children (49.2% male; mean age 11.05 ± 1.4 years) were enrolled. Acne was present in 234/683 (34.3%) of the patients, and its prevalence increased with age being higher after 13 years of age (85/234; 36.3%) and lowest at 9 years of age (14/234; 6%). The majority of the patients suffering from acne showed a mild or almost clear disease state severity (GEA scale 1 or 2) (207/234, 88.5%), whereas severe or very severe forms (GEA scale 4 or 5) represented only 4/234, 1.7% of the cases. CONCLUSIONS: Acne is not a rare disease in pre-adolescent age. Adequate and prompt treatment is also needed in this class of patient to minimize disease burden and potential future disease worsening.


Asunto(s)
Acné Vulgar/epidemiología , Acné Vulgar/terapia , Acné Vulgar/tratamiento farmacológico , Adolescente , Factores de Edad , Instituciones de Atención Ambulatoria/estadística & datos numéricos , Niño , Femenino , Humanos , Italia/epidemiología , Masculino , Pediatría/estadística & datos numéricos , Prevalencia , Estudios Prospectivos , Índice de Severidad de la Enfermedad
16.
Sensors (Basel) ; 7(10): 2484-2491, 2007 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-28903239

RESUMEN

D-Galactose/D-glucose-binding protein from E. coli (GGBP) is a monomer thatbinds glucose with high affinity. The protein structure of GGBP is organized in twoprincipal domains linked by a hinge region that form the sugar-binding site. In this workwe show that the mutant form of GGBP at the amino acid position 182 can be utilized as aprobe for the development of a non-consuming analyte fluorescence biosensor to monitorthe glucose level in diabetes health care.

17.
Antivir Ther ; 11(5): 637-40, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16964833

RESUMEN

BACKGROUND: Pegylated-interferon-alpha (peg-IFN-alpha) is the mainstay of treatment for chronic hepatitis C (CHC). Treatment is often complicated by neutropaenia due to inhibition of haematopoiesis. However, there are no data on the kinetics of granulocyte-colony stimulating factor (G-CSF), a major neutrophil growth factor, in this setting. We therefore evaluated G-CSF synthesis in CHC patients on peg-IFN-alpha treatment. METHODS: A total of 40 CHC patients were studied. None had pre-existing haematological disorders, or hepatitis B virus or HIV coinfection. For controls, 30 healthy subjects were used. Laboratory examinations, including liver function tests, were performed at baseline and monthly over treatment and follow-up. Serum G-CSF was measured in all patients and controls at baseline and in a subgroup of 20 CHC patients also at weeks 2, 4, 24, 48 and 72 after treatment start. RESULTS: CHC patients had a significantly lower pre-treatment neutrophil count (3,256 +/- 1,197 versus 3,804 +/- 859; P = 0.03). Notwithstanding, they showed lower baseline G-CSF serum levels than healthy controls (16.1 +/- 6.2 versus 19.4 +/- 7.5; P = 0.048). Consistently, baseline G-CSF levels were poorly correlated with the neutrophil count in CHC patients (r = -0.2; P = 0.2). Moreover, serum G-CSF levels did not increase in any of the 20 CHC patients during peg-IFN-alpha treatment, despite declining neutrophil counts. CONCLUSIONS: The lower neutrophil counts observed in CHC might be related to an absolute deficiency in G-CSF production. In the human model of neutropaenia induced by peg-IFN-alpha, we show that endogenous G-CSF levels are not physiologically up-regulated to overcome the decline in neutrophil counts. Our study provides a rationale for the evaluation of recombinant human G-CSF treatment in peg-IFN-alpha-induced neutropaenia.


Asunto(s)
Antivirales/efectos adversos , Factor Estimulante de Colonias de Granulocitos/sangre , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/efectos adversos , Neutropenia/inducido químicamente , Polietilenglicoles/efectos adversos , Adulto , Femenino , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Hepatitis C Crónica/sangre , Humanos , Interferón alfa-2 , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Neutropenia/sangre , Neutropenia/tratamiento farmacológico , Proteínas Recombinantes
18.
Chem Commun (Camb) ; (10): 1106-8, 2006 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-16514454

RESUMEN

The text-book Walden cycle which interconverts the stereochemical configurations of chlorosuccinic and malic acids involves a beta-lactone intermediate in preference to an alpha-lactone intermediate because the O(nuc) C Cl angle in the transition structure for the former (174 degrees) is more favourable than that for the latter (139 degrees), as determined by PCM(epsilon = 78.4)/B3LYP/6-31+G* calculations; the smaller ring-strain energy of the beta-lactone contributes little to the reactivity difference.

19.
Infez Med ; 24(4): 278-286, 2016 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-28011962

RESUMEN

Chronic hepatitis B (CHB) treatment aims at long-term suppression of HBV replication and improvement in clinical outcomes. We describe the data of a pilot, non-profit study in which patients with CHB were treated with de novo combination lamivudine-adefovir (LAM-ADV) for at least four years with a view to HBV suppression and resistance prevention, and shifted to tenofovir (TDF) when new antiviral agents were available. Fifty-one HBeAg negative patients were enrolled. Histology was available for 39 patients and data of liver stiffness (LS) for 24 patients at baseline. Serum quantification of HBsAg and HBVDNA was obtained regularly during the follow-up. In 10 and 7 patients, a paired histology and LS were available at the end of LAM-ADV treatment, respectively. The de novo LAM-ADV combination was able to obtain HBVDNA suppression and ALT normalization in one year in most of the patients and in the second year in the remaining. Histology improved in patients with paired biopsy, but tissue HBsAg was present in all but one patient after 48 months of therapy. TDF maintained biochemical and virological response throughout the follow-up. Renal impairment during LAM-ADV therapy improved on shifting to TDF; only in 4 cases was a second shift to entecavir needed. TDF was safe and effective in maintaining HBV DNA suppression achieved by a long-term course of LAM-ADV de novo combination for the treatment of HBeAg-negative CHB.


Asunto(s)
Adenina/análogos & derivados , Antivirales/uso terapéutico , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B Crónica/tratamiento farmacológico , Lamivudine/uso terapéutico , Organofosfonatos/uso terapéutico , Tenofovir/uso terapéutico , Carga Viral/efectos de los fármacos , Adenina/uso terapéutico , Adolescente , Adulto , Farmacorresistencia Viral/genética , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Antígenos de Superficie de la Hepatitis B/efectos de los fármacos , Hepatitis B Crónica/sangre , Humanos , Italia , Masculino , Persona de Mediana Edad , Proyectos Piloto , Resultado del Tratamiento
20.
Transplantation ; 80(9): 1340-3, 2005 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-16314804

RESUMEN

We evaluated clinical evolution and hepatitis B virus (HBV) molecular changes in heart recipients with chronic HBV infection before transplantation, and studied the effects of lamivudine treatment in patients who experienced HBV reactivation. Nine patients with chronic HBV infection who underwent heart transplantation were investigated. HBV surface/core-promoter/precore/core regions were sequenced. Prior to transplantation, all nine patients had consistently normal ALT and low HBV-DNA levels. Seven experienced HBV reactivation after transplantation (ALT elevated, HBV-DNA>200.000 cps/ml). Lamivudine treatment was initially effective in all patients; three patients during the second year of treatment developed lamivudine resistance-associated mutations (rt-L180M, rt-M204V) with severe disease reactivation, remitted after switch to adefovir treatment. No other significant HBV mutations were identified in the genomic regions studied. Immune suppression is crucial in the reactivation of previous inactive HBV infection and in the liver disease progression in heart recipients. Preemptive lamivudine treatment could be useful in the early management of these patients.


Asunto(s)
Cardiopatías/complicaciones , Cardiopatías/cirugía , Trasplante de Corazón , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/fisiopatología , Adenina/análogos & derivados , Adenina/uso terapéutico , Adulto , Alanina Transaminasa/sangre , ADN Viral/sangre , Farmacorresistencia Viral , Femenino , Antígenos del Núcleo de la Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/genética , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/metabolismo , Virus de la Hepatitis B/fisiología , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/virología , Humanos , Inmunosupresores/uso terapéutico , Lamivudine/uso terapéutico , Masculino , Persona de Mediana Edad , Organofosfonatos/uso terapéutico , Periodo Posoperatorio , Regiones Promotoras Genéticas , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Activación Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA